RE
KLDO

RBC Europe’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

RBC Europe’s Portfolio KLDO Stock Details KLDO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-332
Closed -$1.81K – 1267
2021
Q3 		$1.81K Hold
332
– – ﹤0.01% 1136
2021
Q2 		$2.47K Hold
332
– – ﹤0.01% 1105
2021
Q1 		$2.69K Hold
332
– – ﹤0.01% 1055
2020
Q4 		$3.02K Hold
332
– – ﹤0.01% 1021
2020
Q3 		$3.67K Hold
332
– – ﹤0.01% 928
2020
Q2 		$2.47K Hold
332
– – ﹤0.01% 939
2020
Q1 		$2.04K Buy
+332
New +$2.17K ﹤0.01% 915

Other funds holding KLDO

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

RBC Europe's KLDO Position: Q4 2021 in Review

RBC Europe sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q4 2021, closing a stake of 332 shares — an estimated $1.81K sold.

RBC Europe first reported a position in KLDO in Q1 2020 and held it in 7 quarters. The position peaked at $3.67K in Q3 2020. 66 funds tracked by Wall St. Rank hold KLDO as of Q4 2021.

  • RBC Europe reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • RBC Europe sold 332 Kaleido Biosciences, Inc. Common Stock shares in Q4 2021, an estimated $1.81K.
  • RBC Europe first reported a position in Kaleido Biosciences, Inc. Common Stock in Q1 2020 and held it in 7 quarters.
  • RBC Europe's Kaleido Biosciences, Inc. Common Stock position peaked at $3.67K in Q3 2020.
  • 66 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q4 2021.

Based on RBC Europe's 13F filing for Q4 2021, filed 14 Nov 2022.